EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Short Interest Update

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 9,680,000 shares, an increase of 5.6% from the October 15th total of 9,170,000 shares. Based on an average daily trading volume, of 738,100 shares, the short-interest ratio is currently 13.1 days.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Greenwich Wealth Management LLC increased its stake in shares of EyePoint Pharmaceuticals by 8.3% in the 3rd quarter. Greenwich Wealth Management LLC now owns 11,700 shares of the company’s stock valued at $93,000 after purchasing an additional 900 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of EyePoint Pharmaceuticals by 44.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,719 shares of the company’s stock valued at $77,000 after purchasing an additional 1,136 shares during the last quarter. Arizona State Retirement System lifted its position in EyePoint Pharmaceuticals by 9.7% in the second quarter. Arizona State Retirement System now owns 13,251 shares of the company’s stock valued at $115,000 after buying an additional 1,171 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in EyePoint Pharmaceuticals by 26.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,040 shares of the company’s stock valued at $373,000 after purchasing an additional 3,780 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of EyePoint Pharmaceuticals by 68.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company’s stock valued at $82,000 after buying an additional 4,172 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a research note on Saturday, September 21st. Chardan Capital raised their price objective on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Jefferies Financial Group initiated coverage on EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They set a “buy” rating and a $15.00 target price for the company. JPMorgan Chase & Co. decreased their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Finally, HC Wainwright lowered their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, EyePoint Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

EyePoint Pharmaceuticals Trading Up 4.5 %

Shares of NASDAQ EYPT traded up $0.39 during trading on Tuesday, reaching $8.97. 618,088 shares of the company traded hands, compared to its average volume of 936,028. EyePoint Pharmaceuticals has a 12-month low of $5.86 and a 12-month high of $30.99. The firm’s fifty day simple moving average is $9.74 and its 200 day simple moving average is $9.66. The stock has a market cap of $612.20 million, a P/E ratio of -4.48 and a beta of 1.50.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.